SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Nome Químico: 4-(8-Amino-3-((1R)-2-((S)-2-(8-amino-1-(4-(phenylcarbamoyl)phenyl)imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carbonyl)cyclopentyl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Sorrisos: O=C(NC1=CC=CC=C1)C2=CC=C(C=C2)C3=C4N(C([C@@H]5CCCN5C(C6CCC[C@H]6C7=NC(C8=CC=C(C(NC9=NC=CC=C9)=O)C=C8)=C%10N7C=CN=C%10N)=O)=N3)C=CN=C4N
Acalabrutinib Impurity 14 is chemically 4-(8-Amino-3-((1R)-2-((S)-2-(8-amino-1-(4-(phenylcarbamoyl)phenyl)imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carbonyl)cyclopentyl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. Acalabrutinib Impurity 14 is supplied with detailed characterization data compliant with regulatory guideline. Acalabrutinib Impurity 14 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Acalabrutinib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Development and validation of novel HPLC bioanalytical analysis method for acalabrutinib: an anticancer drug in human plasma
By Krishna, G. Atchutarama; Srinivasarao, P.; Patrudu, T. Benarji; Chidanandaswamy, R.
From Asian Journal of Chemistry (2020), 32(10), 2606-2610
Development and validation of UV-spectrophotometric method for simultaneous determination of acamprosate calcium, disulfiram and ondansetron hydrochloride in bulk and tablet dosage forms
By Patil, Purushottam R.; Wagh, Milind P.; Chaudhari, Sanjay R.
From American Journal of PharmTech Research (2016), 6(2), 655-664